Cost-effectiveness of polatuzumab vedotin plus chemoimmunotherapy for untreated diffuse large B-cell lymphoma in China

Cost-effectiveness of polatuzumab vedotin plus chemoimmunotherapy for untreated diffuse large B-cell lymphoma in China

Abstract In recent years, antibody-drug conjugates have become clinically significant in oncology therapeutics. Results from the POLARIX trial revealed that polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) versus rituximab plus cyclophosph...

Full description

Saved in:
Bibliographic Details
Main Authors: Mengya Li, Qian Li, Yinhui Zhang, Changjing Xu, Zhu Chen, Yilan Huang, Longyang Jiang
Format: Article
Language:English
Published: Nature Portfolio 2025-08-01
Series:Scientific Reports
Subjects:
Polatuzumab vedotin
Pola-R-CHP
R-CHOP
Cost-effectiveness
Diffuse large b-cell lymphoma
Online Access:https://doi.org/10.1038/s41598-025-15477-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items